DEVENPORT; Martin

Patent Applications and Registrations

Patent applications and USPTO patent grants for DEVENPORT; Martin.The latest application filed is for "cd80 and cd86 binding protein compositions and uses thereof".

Company Profile

5.4.18

DEVENPORT; Martin - Gaithersburg MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
CD80 and CD86 Binding Protein Compositions and Uses Thereof App 20220259285 - LIU; Yang ; et al.	2022-08-18
CD80 and CD86 Binding Protein Compositions and Uses Thereof App 20220259286 - LIU; Yang ; et al.	2022-08-18
Methods Of Use Of Soluble Cd24 For Treating Systemic Lupus Erythematosus App 20220125874 - LIU; Yang ; et al.	2022-04-28
Methods of Use of Soluble CD24 for Neuroprotection and Remyelination App 20220098278 - Liu; Yang ; et al.	2022-03-31
CD80 and CD86 binding protein compositions and uses thereof Grant 11,261,233 - Liu , et al. March 1, 2	2022-03-01
Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes App 20220000974 - Liu; Yang ; et al.	2022-01-06
Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis App 20220000973 - Liu; Yang ; et al.	2022-01-06
Methods Of Use Of Cd24 For The Prevention And Treatment Of Leukemia Relapse App 20210268061 - Liu; Yang ; et al.	2021-09-02
Methods Of Use Of Cd24 For The Prevention And Treatment Of Graft Versus Host Disease And Mucositis App 20210228680 - Liu; Yang ; et al.	2021-07-29
Anti-cd24 Compositions And Uses Thereof App 20210214458 - Liu; Yang ; et al.	2021-07-15
Use of CD24 Proteins for Treating Leptin-Deficient Conditions App 20210162006 - LIU; Yang ; et al.	2021-06-03
Methods Of Selecting And Designing Safer And More Effective Anti-ctla-4 Antibodies For Cancer Therapy App 20210047410 - Liu; Yang ; et al.	2021-02-18
Mutant Anti-ctla-4 Antibodies With Improved Immunotherapeutic Effect But Attenuated Adverse Effects App 20210040212 - Liu; Yang ; et al.	2021-02-11
Use of CD24 proteins for treating leptin-deficient conditions Grant 10,799,558 - Liu , et al. October 13, 2	2020-10-13
Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof App 20200283526 - LIU; Yang ; et al.	2020-09-10
Methods Of Use Of Soluble Cd24 For Treating Immune Related Adverse Events In Cancer Therapies App 20200197485 - LIU; Yang ; et al.	2020-06-25
Methods Of Use Of Soluble Cd24 For Neuroprotection And Remyelination App 20200181235 - LIU; Yang ; et al.	2020-06-11
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof Grant 10,618,960 - Liu , et al.	2020-04-14
CD80 and CD86 Binding Protein Compositions and Uses Thereof App 20190263889 - LIU; Yang ; et al.	2019-08-29
Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof App 20190127468 - LIU; Yang ; et al.	2019-05-02
Use of CD24 Proteins for Treating Leptin-Deficient Conditions App 20190038716 - LIU; Yang ; et al.	2019-02-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.